Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business
TAE Life Sciences (TLS)
About
  2. Companies
  3. TAE Life Sciences (TLS)
  4. Products
  5. TAE Life Sciences - Boron Neutron ...

TAE Life Sciences - Boron Neutron Capture Therapy

SHARE

Gordon Locher first proposed Boron Neutron Capture Therapy (BNCT) in 1936. Clinical investigation and treatments were first introduced in the USA in the 1950s and showed promising results. Historically, BNCT clinical studies have been carried out using boronophenylalanine (BPA) and neutrons derived from the core of a nuclear reactor. While the clinical outcomes have been encouraging, the availability of better boron-10 compounds and access to a neutron source posed a significant barrier to clinical research and adoption of BNCT as a practical cancer therapy.

Most popular related searches
cancer cell destruction
clinical outcome
clinical study
cancer cell
cancerous target
patient positioning
respiratory gating
patient throughput
cancer treatment
patient care

Despite this challenge, approximately 2,000 patients have been treated at research sites worldwide and have shown favorable clinical outcomes in patients with glioblastomas, head and neck, and other challenging cancers.

Now, a renaissance in BNCT is occurring with the availability of new accelerator-based neutrons sources and novel synthesis of boron-10 target drugs, allowing clinical research to expand with the goal to have BNCT available as a new treatment option for patients everywhere.

The secondary radiation reaction from BNCT, with cellular-level precision, spares more healthy tissues and can potentially treat cancers that otherwise have few treatment options.

Global research shows BNCT provides the following benefits:

Biophysical Precision

  • Effective in treating recurrent, multiple, and untreated cancers
  • Targets cancer at cellular level
  • Selectively destroys cancer cells
  • Eliminates the need for respiratory gating and internal markers

Efficient Treatment

  • One to two treatment sessions
  • Treats primary and undetected local microscopic cancer cells in parallel
  • Potential for more patient throughput than other radiation therapies

Better Patient Experience

  • Does not require high-level patient positioning, improving patient comfort and reducing staff workload
  • Potential to greatly reduce side effects and improve patient quality of life